Brentuximab Vedotin and Nivolumab for the Treatment of Relapsed/Refractory Classic Hodgkin Lymphoma Previously Treated With Brentuximab Vedotin or Checkpoint Inhibitors

This trial is testing a combination of brentuximab vedotin and nivolumab in patients with classical Hodgkin lymphoma whose cancer has relapsed after initial treatment with one of these drugs (but not both). **You may be eligible if...** - You are 12 years of age or older with classical Hodgkin lymphoma - Your cancer came back after one prior treatment that included either brentuximab or nivolumab/pembrolizumab — but not both - You have not had a stem cell transplant - You have measurable cancer on imaging - Your blood counts and organ function are adequate **You may NOT be eligible if...** - You have had chemotherapy or radiation within the past 2 weeks - You have an active autoimmune disease - Your lymphoma has spread to the brain - You have active hepatitis B or C - You have had another cancer recently (within 2 years) that could limit survival - You are pregnant or unwilling to use contraception Talk to your doctor to see if this trial is right for you.